Literature DB >> 18790793

Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein.

Claire Germain1, Emmanuelle Campigna, Imed Salhi, Sébastien Morisseau, Isabelle Navarro-Teulon, Jean-Pierre Mach, André Pèlegrin, Bruno Robert.   

Abstract

Natural killer (NK) cells are at the crossroad between innate and adaptive immunity and play a major role in cancer immunosurveillance. NK cell stimulation depends on a balance between inhibitory and activating receptors, such as the stimulatory lectin-like receptor NKG2D. To redirect NK cells against tumor cells, we designed bifunctional proteins able to specifically bind tumor cells and to induce their lysis by NK cells, after NKG2D engagement. To this aim, we used the 'knob into hole' heterodimerization strategy, in which 'knob' and 'hole' variants were generated by directed mutagenesis within the CH3 domain of human IgG1 Fc fragments fused to an anti-CEA or anti-HER2 scFv or to the H60 murine ligand of NKG2D, respectively. We demonstrated the capacity of the bifunctional proteins produced to specifically coat tumor cells surface with H60 ligand. Most importantly, we demonstrated that these bifunctional proteins were able to induce an NKG2D-dependent and antibody-specific tumor cell lysis by murine NK cells. Overall, the results show the possibility to redirect NK cytotoxicity to tumor cells by a new format of recombinant bispecific antibody, opening the way of potential NK cell-based cancer immunotherapies by specific activation of the NKG2D receptor at the tumor site.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790793      PMCID: PMC2759461          DOI: 10.1093/protein/gzn047

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  58 in total

Review 1.  New aspects of natural-killer-cell surveillance and therapy of cancer.

Authors:  Mark J Smyth; Yoshihiro Hayakawa; Kazuyoshi Takeda; Hideo Yagita
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

2.  An efficient route to human bispecific IgG.

Authors:  A M Merchant; Z Zhu; J Q Yuan; A Goddard; C W Adams; L G Presta; P Carter
Journal:  Nat Biotechnol       Date:  1998-07       Impact factor: 54.908

Review 3.  Control of infections by NK cells.

Authors:  C H Tay; E Szomolanyi-Tsuda; R M Welsh
Journal:  Curr Top Microbiol Immunol       Date:  1998       Impact factor: 4.291

4.  Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.

Authors:  Daniela Pende; Paola Rivera; Stefania Marcenaro; Chien-Chung Chang; Roberto Biassoni; Romana Conte; Marek Kubin; David Cosman; Soldano Ferrone; Lorenzo Moretta; Alessandro Moretta
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

5.  Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA).

Authors:  B Robert; M Dorvillius; F Buchegger; V Garambois; J C Mani; M Pugnières; J P Mach; A Pèlegrin
Journal:  Int J Cancer       Date:  1999-04-12       Impact factor: 7.396

6.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Authors:  S Bauer; V Groh; J Wu; A Steinle; J H Phillips; L L Lanier; T Spies
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

Review 7.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.

Authors:  F Garrido; F Ruiz-Cabello; T Cabrera; J J Pérez-Villar; M López-Botet; M Duggan-Keen; P L Stern
Journal:  Immunol Today       Date:  1997-02

8.  Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy.

Authors:  P Clarke; J Mann; J F Simpson; K Rickard-Dickson; F J Primus
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

9.  A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.

Authors:  M A Arndt; J Krauss; S M Kipriyanov; M Pfreundschuh; M Little
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

10.  The molecular and functional characterization of a dominant minor H antigen, H60.

Authors:  S Malarkannan; P P Shih; P A Eden; T Horng; A R Zuberi; G Christianson; D Roopenian; N Shastri
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

View more
  4 in total

Review 1.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

Review 2.  Regulation of immune cell function and differentiation by the NKG2D receptor.

Authors:  Biljana Zafirova; Felix M Wensveen; Maja Gulin; Bojan Polić
Journal:  Cell Mol Life Sci       Date:  2011-09-06       Impact factor: 9.261

3.  VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer.

Authors:  Wei Xie; Fang Liu; Youfu Wang; Xueyan Ren; Tong Wang; Zhiguo Chen; Mingying Tang; Fumou Sun; Zhaoting Li; Min Wang; Juan Zhang
Journal:  Oncotarget       Date:  2016-03-29

4.  A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies.

Authors:  Bo Wang; Jun Lin; Matthew R Hoag; Meredith Wright; Mingjun Ma; Wenyan Cai; Sachith Gallolu Kankanamalage; Yue Liu
Journal:  Antib Ther       Date:  2022-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.